# US 2010/0137391 A1 · Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137391 A1
- Document ID: US20100137391A1
- Status: Published application
- Kind: A1
- Application number: 11/991,859
- Filed: 2006-09-13
- Published: 2010-06-03
- Earliest claimed: 2005-09-15
- Inventors: Ryo Yoshimoto; Akane Ishihara; Akio Kanatani; Shigeru Tokita
- Web page: https://patentgrep.com/patent/US20100137391A1

## CPC

- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed are: novel use of an agonist histamine receptor H3 (e.g., Imetit) for prevention of obesity or the reduction of food intake; a method for evaluation of a compound for use as a therapeutic agent targeted to histamine receptor HR protein; and a compound provided by the method.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method of treating a disease selected from a lipid metabolic disease and a glucose metabolic disease in a patient in need of such treatment comprising administration of a therapeutically effective amount of a histamine H3 agonist.

### Claim 14 (depends on 13)

The method according to claim 13 wherein the histamine H3 agonist is a compound of Formula (I):
wherein R1 and R2 represent a hydrogen atom or a lower alkyl group, or when both m and n are 0, R1 and R2 represent the following (i) or (ii):
(i) R1 and R2 together form 5- or 6-membered aliphatic group; or
(ii) R1 and the nitrogen atom of NH2 in Formula (I) together form a 5- or 6-membered ring,
X represents CH2 or S, and
m and n independently represent 0 or 1,
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein in the compound of Formula (I), both m and n are 0, or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 14)

The method according to claim 14, wherein in the compound of Formula (I), both m and n are 1, or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 14)

The method according to claim 14, wherein, the histamine H3 agonist compound of is selected from:
1 -amino-2-(1H-imidazol-4-yl)cyclopentane,
3-(1H-imidazol-4-yl)-2-butanamine,
2-methyl-3 -(1 H-imidazol-4-yl)pyrrolidine,
1-methyl-2-(1H-imidazol-4-yl)cyclohexylamine,
1 H-imidazol-4-butanimidamide,
α-methylhistamine, and
carbamimidothioic acid 2-(1H-imidazol-4-yl)ethyl ester;
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 13)

The method according to claim 13 wherein the disease is a lipid metabolic disease selected from: obesity, eating disorder, diabetes, hyperlipidemia, hypercholesterolemia, and fatty liver.

### Claim 19

A method for assaying a compound used in the treatment of a lipid metabolic disease, comprising steps of:
introducing a histamine H3 receptor gene into a cell, so as to prepare a cell that expresses a histamine H3 receptor;
bringing a test compound into contact with said cell; and
detecting the specific binding of said test compound to said histamine H3 receptor.

### Claim 20

A method for assaying a compound used in the treatment of a lipid metabolic disease, comprising steps of:
introducing a histamine H3 receptor gene into a cell, so as to prepare a cell that expresses a histamine H3 receptor;
bringing a test compound into contact with said cell;
measuring an activity of an intracellular signaling agent generated as a result of the contact; and
comparing the thus measured activity with an activity of the intracellular signaling agent in a case where a test compound is not contacted with said cell.

### Claim 21

A method for assaying a compound used in the treatment of a lipid metabolic disease, comprising steps of:
introducing a histamine H3 receptor gene into a cell, so as to prepare a cell that expresses a histamine H3 receptor;
bringing a test compound into contact with said cell;
measuring an expression level of the histamine H3 receptor or an intracellular signaling agent mediated by the histamine H3 receptor; and
selecting a test compound that has increased or decreased the expression level of the histamine H3 receptor or the intracellular signaling agent mediated by the histamine H3 receptor, when compared with a case where such a test compound is not contacted with said cell.

### Claim 22

A method for assaying a compound used in the treatment of a lipid metabolic disease, comprising steps of:
bringing a test compound into contact with a histamine H3 receptor; and
detecting a change in the activity of the histamine H3 receptor due to the contact.

### Claim 23 (depends on 19)

The method for assaying a compound according claim 19, wherein said compound is a histamine H3 agonist.

### Claim 24 (depends on 20)

The method for assaying a compound according claim 20, wherein said compound is a histamine H3 agonist.

### Claim 25 (depends on 22)

The method for assaying a compound according claim 22, wherein said compound is a histamine H3 agonist.

### Claim 26 (depends on 19)

A histamine H3 agonist, wherein the agonist is isolated by the method for assaying a compound according to claim 19.

### Claim 27 (depends on 20)

A histamine H3 agonist, wherein the agonist is isolated by the method for assaying a compound according to claim 20.

### Claim 28 (depends on 22)

A histamine H3 agonist, wherein the agonist is isolated by the method for assaying a compound according to claim 22.
